DISCOVERY AND DEVELOPMENTAL THERAPEUTICS (DDT)

发现和开发疗法（DDT）

• 批准号: 7944885
• 负责人: Fadlo Raja Khuri
• 金额: $ 7.98万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-07 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7944885
• 关键词: Antineoplastic Agents; Area; Biological; Biological Markers; Biology; Biomedical Research; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Immunology Science; Chemicals; Chemoprevention; Clinical Trials; Developmental Therapeutics Program; Environment; Epigenetic Process; Epithelial; Fostering; Funding; Goals; Hematologic Neoplasms; Institutes; Life Cycle Stages; Malignant Neoplasms; Mission; Modality; Molecular; Molecular Target; Nanotechnology; New Agents; Operative Surgical Procedures; Paper; Pathway interactions; Patients; Peer Review; Population Sciences; Prevention; Prevention approach; Public Health Schools; Publishing; Radiation; Reproduction spores; Research; Research Personnel; Science; Signal Pathway; Solid; Solid Neoplasm; Source; Testing; Tissues; Translating; Translations; base; cancer genetics; cancer immunotherapy; cancer therapy; college; drug development; drug discovery; innovative technologies; interest; medical schools; member; multimodality; nanotherapeutic; novel therapeutic intervention; prevent; programs; small molecule; therapeutic development; translational clinical trial; tumor

Program 3. Discovery and Developmental Therapeutics (DDT): The overall scientific goal of the Cancer Discovery and Developmental Therapeutics (DDT) Program is to enhance the discovery of new agents and advance their translation into the prevention and treatment of patients with cancer. The program has two full specific aims, and two major developing aims. The overall goal is to foster a highly collaborative team science environment, building on the existing strong ties with the MPB, CGE and CCPS Programs, to promote molecular target-based cancer drug discovery and to facilitate translational clinical trials for effective therapeutic development. To achieve this goal, the Program is organized with the following foci: (1) To identify small molecule modulators of tumor-addicted signaling pathways for cancer drug discovery; (2) To carry out mechanism-driven clinical trials for cancer drug development to rapidly move new agents to patients; (3) To translate discoveries in cancer immunology into mechanistically driven clinical trials enhancing the therapy of patients with hematologic malignancies and immuno-responsive solid tumors; (4) To test promising agents early in their life cycle in the multi-modality setting using mechanism-based clinical trials in conjunction with optimized chemo-radiation, radiation or surgery. We plan to achieve the goal of developing novel therapeutic approaches to the prevention and treatment of cancer through close intra- and inter-programmatic interactions by focusing on such areas as: (1) chemoprevention, (2) molecularly-targeted therapy, (3) new drug discovery, (4) biological interaction between epithelial and surrounding tissue, (5) nanotherapeutics, (6) cancer immunotherapy, (7) biomedical research platforms using innovative technology to prevent and treat tumors, and (8) translational multimodality research for advanced solid malignancies. The DDT Program comprises a diverse group of 45 members from 15 different departments within the School of Medicine, the School of Public Health and Emory College. The DDT Program has total peerreviewed program funding of $23 M, of which NCI funding represents $17.5M ($13.6M direct). In addition, there is a total of $1.9 M in non-peer-reviewed support from various sources. Program members have published a total of 535 papers during the last five years, of which 47% are intra-programmatic and 53% are inter-programmatic.

计划3。发现与发展治疗学（DDT）：癌症的总体科学目标 发现和发育治疗学（DDT）计划是增强新代理的发现和 将他们转化为预防和治疗癌症患者。该程序有两个完整 具体目标和两个主要的发展目标。总体目标是培养一个高度协作的团队 科学环境是基于与MPB，CGE和CCPS计划的现有牢固联系的， 促进基于分子目标的癌症药物发现并促进转化临床试验有效 治疗发展。为了实现这一目标，该程序以以下焦点进行组织：（1） 鉴定肿瘤成瘾的信号传导途径的小分子调节剂，以发现癌症药物的发现； （2）至 进行癌症药物开发的机理驱动临床试验，以迅速将新药物转移到 患者; （3）将癌症免疫学的发现转化为机械驱动的临床试验 增强血液系统恶性肿瘤患者的治疗和免疫反应性实体瘤； （4） 使用基于机制的临床来测试多模式设置的生命周期的早期生命周期的有希望的代理 试验结合了优化的化学辐射，放射或手术。 我们计划实现开发新型治疗方法的目标，以预防和治疗 通过关注以下区域的关注： （1）化学预防，（2）分子靶向疗法，（3）新药发现，（4）生物学相互作用 （5）纳米疗法，（6）癌症免疫疗法，（7）生物医学之间 使用创新技术预防和治疗肿瘤的研究平台和（8）转化多模式 研究高级固体恶性肿瘤的研究。 DDT计划由来自15个不同部门的45名成员组成 公共卫生和埃默里学院医学院。 DDT程序的同行总计 计划资金为$ 23 m，其中NCI资金代表1,750万美元（直接1360万美元）。此外， 来自各种来源的未经Per审查的支持总共有1.9 m $ 1.9 m。计划成员有 在过去的五年中，总共发表了535篇论文，其中47％是概括性的，53％为 编程间。